A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III, Long-Term Safety and Tolerability Study of TC-5214 (S-mecamylamine) as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit an Inadequate response to Antidepressant Therapy. Astra Zeneca, S.C. Lapham and M. Hollifield , Principal Investigators 2010 - 2012
A Phase 2, multi-center, randomized, double-blind, placebo controlled, adaptive study of the safety and efficacy of RDC-0313 in adults with alcohol dependence. Alkermes Inc., S.C. Lapham, Principal Investigator 2009 - 2010
Mental Illness and Community Reentry in a Multi-Ethnic Population of Female Inmates. NIMH Grant # R34MH082186, C. Willging, Principal Investigator 01/2009 ? 09/2011
A Phase II Multicenter, Randomized, Double-Blind, Two-Stage Clinical Trial to Evaluate the Efficacy and Safety of MK-0594 in Patients with Alcohol Dependence. Merck and Co., Inc., S.C. Lapham, Principal Investigator 2008 - 2010
A Phase 2 Study of LY686017 Compared with Placebo for the Treatment of Alcohol Dependence. Eli Lilly and Company, S.C. Lapham, Principal Investigator 2008 - 2009
CPP-02001Vigabatrin for the treatment of Methamphetamine dependence: A Phase II Study. Catalyst Pharmaceutical Partners, S.C. Lapham, Principal Investigator 2008 - 2009
Total Community Approach Evaluation. ValueOptions/State of New Mexico, C. Willging, Principal Investigator 03/2008 - 06/2008
Developing a Framework for a Tribal Comprehensive Impaired Driving Program, NHTSA DTNH22-06-D-00035: C. Willging, Project Director 08/2007 - 05/2010
Border Area Mental Health Services, Inc. Methamphetamine Prevention Project, E. Lilliott, Principal Investigator & Local Evaluator 07/2007 - 09/2010
Clinical Home Evaluation. Technical Assistance Collaborative/State of New Mexico, C. Willging, Principal Investigator/Anthropologist 08/2007 - 06/2008
Vivitrol for Reducing Driving While Impaired Behavior Among DUI Offenders, A Pilot Study. Cephalon, Inc. ISS Program, S.C. Lapham, Principal Investigator 04/2007 - 04/2009
Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of ALK29 in Adults with Alcohol Dependence. Alkermes, Inc., S.C. Lapham, Principal Investigator 2006 - 2007
Border Area Mental Health Services, Inc. SPF-SIG Contract: E. Lilliott, Principal Investigator & Local Evaluator 04/2006 - 09/2010
Drug Use, Ethnicity, and Help-Seeking among Rural Youth. NIDA Grant # R21DA018237, C. Willging, Principal Investigator 04/2005 - 03/2008
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Nalmefene HCL in the Treatment of Pathological Gambling. Somaxon, S.C. Lapham, Principal Investigator 2005 - 2006
A Phase 3, double Blind, Randomized, MultiSite Trial of the Efficacy, Safety, and Tolerability of the Fixed Combination Torcetrapib/Atorvastatin Administered Orally, Once Daily for 12 months, Compared to Atorvastatin Alone, Titrated Based on NCEP ATP III LDL C Goals in Subjects with Frederickson Types II A and IIB Dyslipidemias. Pfizer, S.C. Lapham, Principal Investigator 2004 - 2006
A multi-center, randomized, double-blind, placebo-controlled, flexible dose study to assess the safety and efficacy of Topiramate in the treatment of alcohol dependence. Ortho McNeil Pharmaceutical, Inc., S.C. Lapham, Principal Investigator 2004 - 2006
Long Term Recovery Among Convicted Drunk Drivers. NIAAA Grant # R01AA14750, S.C. Lapham, Principal Investigator, 07/2004 ? 06/2010
Randomized Interventions for Substance-Using Kids, NIDA Grant # R21DA016571, J. C?de Baca, Principal Investigator 04/2004 ? 09/2007
Testing explicit theoretical models of drinking/driving, NIAAA Grant # R03 AA013712, S.C. Lapham, Principal Investigator 04/2003 - 09/2005
DWI Research Speaker Series - DWI Resource Center. S.C. Lapham, Project Director 12/2003 - 10/2004
"Did Reinstating Sunday Liquor Sales Impact Alcohol-Related Traffic Crashes in New Mexico?" The Robert Wood Johnson Foundation Grant # 04966811, G. McMillan, Principal Investigator 08/2003 - 07/2004
Develop a baseline instrument to screen court-mandated offenders; who have an interlock ignition system installed on their vehicles. WESTAT, Inc., S.C. Lapham, Project Director 06/2003 - 06/2004
Office based prescribing and community pharmacy dispensing study: providing methadone maintenance treatment through community physicians and pharmacies. NIDA, C. Gregory, Principal Investigator. 10/2003 ? 12/2004
A 6 week, Randomized, Open ? Label, Comparative Study to Evaluate the Efficacy and Safety of Rosuvastatin and Atorvastatin in the Treatmentof Hypercholesterolemia in Hispanic Subjects. Astra Zeneca, S.C. Lapham, Principal Investigator 2003 - 2005
Effects of a new policy allowing methadone maintenance treatment in a New Mexico jail. The Robert Wood Johnson Foundation Grant # 047654, S.C. Lapham, Principal Investigator 01/2003 ? 01/2005
The Effect of Ortho Tri-cylene on bone Mineral Density in Pediatric Subjects with Anorexia Nervosa: A Double Blind Placebo Controlled Study. Ortho McNeil, S.C. Lapham, Principal Investigator 2002 - 2003
ALK 21-003, ALK 21-003-EXT, and ALK 21-010 A Phase III, multi - center, randomized, double-blind, placebo controlled study of the efficacy and safety of Medisorb Naltrexone in alcohol dependent adults. Alkermes, Inc., S.C. Lapham, Principal Investigator 2001 ? 2006
Naltrel 99-03 safety and efficacy of Naltrexone Depot in treatment of alcohol dependence. Drug Abuse Sciences, S.C. Lapham, Principal Investigator 2001 - 2003
Randomized sanctions to reduce drunk-driving recidivism, NIAAA Grant # R01AA012791, S.C. Lapham, Principal Investigator 09/2000 ? 07/2006
Follow-up of women DWI offenders 5 years after screening, NIAAA Grant # R01AA009620, S.C. Lapham, Principal Investigator 01/1994 - 12/1998
Truancy intervention program at Albuquerque Public Schools. Sociological Initiatives Foundation, J. C?deBaca, Principal Investigator 10/2001 - 09/2002
Consequences of the 1998 drive-up liquor window closure in NM, The Robert Wood Johnson Foundation Grant # 037371, S.C. Lapham, Principal Investigator 10/2000 - 9/2002
Y-STOP, a program to provide substance abuse and health screening for juveniles. McCune Charitable Foundation. J. C?deBaca, Principal Investigator 07/1999 - 06/2002
Meta analysis of research screening programs for convicted drunk driving offenders. AAA Foundation for Traffic Safety, I. Chang, Principal Investigator 04/1999 - 05/2000
Substance abuse intervention for healthcare workers. Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Prevention, S.C. Lapham, Principal Investigator 09/1997 - 12/2000
612 Encino Place NE